GLPG Stock Recent News

Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries.

Mechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos' CAR-T cell therapies through BCA's network in the U.S.

Galapagos NV (NASDAQ:GLPG ) Q1 2024 Results Conference Call May 3, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Investor Relations Paul Stoffels - Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating Officer Jeevan Shetty - Head of Development Oncology Conference Call Participants Xian Deng - UBS Philip Nadeau - TD Cowen Nevin Varghese - RBC Capital Markets Judah Frommer - Morgan Stanley Jason Gerberry - Bank of America Jacob Mekhael - KBC Securities Sean McCutcheon - Raymond James Sebastiaan van der Schoot - VLK Shan Hama - Jefferies Sofie Van Gijsel Welcome all to the audio webcast of Galapagos' Q1 2024 Results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos.

The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.

Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants Emily Field - Barclays Jason Gerberry - Bank of America Mike Ulz - Morgan Stanley Brian Balchin - Jefferies Xian Deng - UBS Phil Nadeau - TD Cowen Dane Leone - Raymond James Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos H1 2023 Financial Results Conference Call.

Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.

Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.